((自动化翻译由路透提供,请见免责声明 ))
路透12月20日 - Vertex制药公司周五表示,美国食品和药物管理局已经批准了该公司治疗一种罕见的渐进性遗传疾病的下一代疗法 ,从而扩大了该公司在囊性纤维化市场的主导地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.